
|Videos|January 31, 2021
Glaukos COO shares product updates, 2021 pipeline
Author(s)David Hutton, Alex Delaney-Gesing
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Non-invasive electrical stimulation therapy for intermediate dry AMD: improved retinal health and visual acuity
2
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
3
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
4
Beyond the phenotype: Aqueous humor sampling moves retinoblastoma toward personalized therapy
5












